Novartis AG Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (48)

Latest Posts

About This Stock More About This Stock
Novartis-Backed Ionis Subsidiary Akcea Maps A $100M IPO As It Steers A Lead Drug To Regulators
Article By: Lorimer Wilson
Monday, March 27, 2017 6:16 PM EDT
Ionis Pharmaceuticals, Inc. subsidiary Akcea — a specialist in lipid disorders — is shooting for a $100 million IPO, with Novartis coming in to support the move with an extra $50 million to purchase a growing equity stake.
In this article: NVS, IONS
Read
Novartis Spinning Out 2 Phase IIb-Ready Drugs To PureTech Health For An Equity Stake
Article By: Lorimer Wilson
Friday, March 24, 2017 1:10 PM EDT
Novartis is spinning out a pair of Phase IIb-ready drugs to Boston-based start-up PureTech Health, setting up a subsidiary called resTORbio which it will now fund, in tranches, with $15 million.
In this article: NVS
Read
Novartis Flubs Primary Endpoint With Heart Drug Serelaxin
Article By: Lorimer Wilson
Wednesday, March 22, 2017 11:00 AM EDT
Novartis has reported that its 4-year study of the heart drug serelaxin has flubbed the primary endpoint, failing to significantly cut the rate of cardiovascular death or reduce worsening heart failure among patients with acute heart failure.
In this article: NVS Also: REGN, AMGN
Read
Novartis Leadership In Psoriasis Therapies Could Be Consolidated With New Drug "Cosentyx"
Article By: Lorimer Wilson
Wednesday, March 22, 2017 1:00 AM EDT
The pharma giant Novartis is looking to consolidate its hold on the lead role for new therapies for psoriasis with some remarkable data suggesting the drug could act as a disease modifier for a significant group of patients.
In this article: NVS Also: JNJ, LLY, VRX
Read
Competition Increases Between Novartis, Lilly & Pfizer For Approval Of New Breast Cancer Drug
Article By: Lorimer Wilson
Monday, March 20, 2017 12:38 PM EDT
Just one week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly & Co. has announced that its long-awaited Phase III readout for its rival drug "abemaciclib" looks good albeit remaining far behind Pfizer in the CDK 4/6 game.
In this article: LLY, NVS, PFE
Read

PARTNER HEADLINES

Latest Tweets for $NVS

No tweets yet!